Asahi Kasei Bioprocess (AKB) and Axolabs have announced a strategic partnership in the field of oligonucleotide therapeutics, aiming to accelerate the development and commercialization of these innovative therapies. The collaboration will establish an oligonucleotide cGMP manufacturing facility in Berlin, spanning an impressive 59,000 square feet.

Oligonucleotide therapies offer a targeted approach to treating diseases by modulating gene expression, splicing, and protein production. With the potential to address a wide range of conditions, including genetic disorders, cancer, and viral infections, these therapies promise to transform patient care worldwide.

Axolabs, a CRDMO specializing in drug substances for oligonucleotide-based therapeutics, is spearheading the establishment of the new GMP manufacturing hub. Leveraging the expertise of AKB in oligosynthesis equipment and Axolabs' proficiency in therapeutic development, the facility is poised to play a pivotal role in advancing therapeutic breakthroughs.

"We are thrilled to join forces with Axolabs in this transformative endeavor," said Chris Rombach, SVP of Sales and Marketing at AKB. "Our combined technical expertise and strategic alignment will bolster our commitment to meet and exceed the growing needs of the oligonucleotide therapeutics field," added Rombach.

Thomas Rupp, Managing Director of Technology and Production at Axolabs, expressed confidence in the partnership's potential, stating, "Partnering with AKB provides a unique opportunity to blend our respective strengths. We are confident that this collaboration will foster innovation and drive the production of high-quality oligonucleotide therapeutics."

The facility, equipped to accommodate various production scales, from small to large/commercial, will benefit from AKB's advanced suite of oligo manufacturing equipment. The operations are slated to commence in late 2024.